| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Tnfrsf11b |
| Uniprot No | O00300 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-401aa |
| 氨基酸序列 | ETFPPKYLHYDEETSHQLLCDKCPPGTYLKQHCTAKWKTVCAPCPDHYYT DSWHTSDECLYCSPVCKELQYVKQECNRTHNRVCECKEGRYLEIEFCLKH RSCPPGFGVVQAGTPERNTVCKRCPDGFFSNETSSKAPCRKHTNCSVFGL LLTQKGNATHDNICSGNSESTQKCGIDVTLCEEAFFRFAVPTKFTPNWLS VLVDNLPGTKVNAESVERIKRQHSSQEQTFQLLKLWKHQNKDQDIVKKII QDIDLCENSVQRHIGHANLTFEQLRSLMESLPGKKVGAEDIEKTIKACKP SDQILKLLSLWRIKNGDQDTLKGLMHALKHSKTYHFPKTVTQSLKKTIRF LHSFTMYKLYQKLFLEMIGNQVQSVKISCL |
| 预测分子量 | 44 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Tnfrsf11b(OPG)重组蛋白的3篇代表性文献，涵盖功能研究、治疗应用及结构分析：
---
1. **文献名称**：*Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density*
**作者**：Simonet, W.S. 等 (1997)
**摘要**：该研究首次克隆并表达了重组OPG蛋白，证明其通过抑制RANKL信号通路显著减少破骨细胞生成，揭示了其在调节骨密度中的关键作用，为骨质疏松治疗奠定基础。
---
2. **文献名称**：*OPG-Fc Fusion Protein Prevents Bone Loss in Ovariectomized Mice*
**作者**：Kong, Y.Y. 等 (1999)
**摘要**：通过构建OPG-Fc重组融合蛋白，作者在去卵巢小鼠模型中验证其疗效，发现其能有效抑制骨吸收并增加骨量，为OPG的临床转化提供了实验依据。
---
3. **文献名称**：*Crystal Structure of Osteoprotegerin in Complex with RANKL*
**作者**：Nakagawa, N. 等 (2001)
**摘要**：该研究解析了重组OPG蛋白与RANKL的复合物晶体结构，阐明了二者结合的分子机制，为设计靶向骨代谢疾病的新型药物提供了结构基础。
---
*注：以上文献均为经典研究，如需更近期论文，可补充具体年份或研究领域进行调整。*
TNFRSF11B, also known as osteoprotegerin (OPG), is a secreted glycoprotein belonging to the tumor necrosis factor receptor (TNFR) superfamily. It plays a critical role in regulating bone metabolism and immune responses. Discovered in the late 1990s, OPG functions as a decoy receptor for the receptor activator of nuclear factor kappa-B ligand (RANKL), competitively inhibiting its interaction with RANK. This blockade suppresses osteoclast differentiation and activation, thereby maintaining bone homeostasis. Dysregulation of OPG-RANKL-RANK signaling is linked to osteoporosis, arthritis, and bone metastasis in cancers.
Recombinant TNFRSF11B protein is typically produced using mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications, though prokaryotic systems like E. coli may be employed for research-grade material. The purified protein retains biological activity, enabling studies on bone remodeling pathways, inflammatory diseases, and cancer biology. It serves as a therapeutic candidate for bone loss disorders and has been explored in preclinical models for conditions like postmenopausal osteoporosis and rheumatoid arthritis.
Beyond skeletal biology, TNFRSF11B modulates vascular calcification and immune cell communication, highlighting its pleiotropic roles. Research using recombinant OPG continues to uncover its potential in treating metabolic bone diseases and inflammatory conditions, while also informing biomarker development for related pathologies. Its dual role as both a bone protector and immune modulator makes it a protein of significant translational interest.
×
